Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Identifieur interne : 003F85 ( Ncbi/Merge ); précédent : 003F84; suivant : 003F86Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Auteurs : Tarek Mohamed Abd El-Aziz [États-Unis, Égypte] ; James D. Stockand [États-Unis]Source :
- Infection, Genetics and Evolution [ 1567-1348 ] ; 2020.
Abstract
Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year.
Url:
DOI: 10.1016/j.meegid.2020.104327
PubMed: NONE
PubMed Central: 7166307
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001788
- to stream Pmc, to step Curation: 001788
- to stream Pmc, to step Checkpoint: 000116
Links to Exploration step
PMC:7166307Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status</title><author><name sortKey="El Aziz, Tarek Mohamed Abd" sort="El Aziz, Tarek Mohamed Abd" uniqKey="El Aziz T" first="Tarek Mohamed Abd" last="El-Aziz">Tarek Mohamed Abd El-Aziz</name><affiliation wicri:level="2"><nlm:aff id="af0005">Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="af0010">Zoology Department, Faculty of Science, Minia University, El-Minia 61519, Egypt</nlm:aff><country xml:lang="fr">Égypte</country><wicri:regionArea>Zoology Department, Faculty of Science, Minia University, El-Minia 61519</wicri:regionArea><wicri:noRegion>El-Minia 61519</wicri:noRegion></affiliation></author><author><name sortKey="Stockand, James D" sort="Stockand, James D" uniqKey="Stockand J" first="James D." last="Stockand">James D. Stockand</name><affiliation wicri:level="2"><nlm:aff id="af0005">Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmc">7166307</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166307</idno><idno type="RBID">PMC:7166307</idno><idno type="doi">10.1016/j.meegid.2020.104327</idno><idno type="pmid">NONE</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">001788</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001788</idno><idno type="wicri:Area/Pmc/Curation">001788</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001788</idno><idno type="wicri:Area/Pmc/Checkpoint">000116</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000116</idno><idno type="wicri:Area/Ncbi/Merge">003F85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status</title><author><name sortKey="El Aziz, Tarek Mohamed Abd" sort="El Aziz, Tarek Mohamed Abd" uniqKey="El Aziz T" first="Tarek Mohamed Abd" last="El-Aziz">Tarek Mohamed Abd El-Aziz</name><affiliation wicri:level="2"><nlm:aff id="af0005">Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="af0010">Zoology Department, Faculty of Science, Minia University, El-Minia 61519, Egypt</nlm:aff><country xml:lang="fr">Égypte</country><wicri:regionArea>Zoology Department, Faculty of Science, Minia University, El-Minia 61519</wicri:regionArea><wicri:noRegion>El-Minia 61519</wicri:noRegion></affiliation></author><author><name sortKey="Stockand, James D" sort="Stockand, James D" uniqKey="Stockand J" first="James D." last="Stockand">James D. Stockand</name><affiliation wicri:level="2"><nlm:aff id="af0005">Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><series><title level="j">Infection, Genetics and Evolution</title><idno type="ISSN">1567-1348</idno><idno type="eISSN">1567-7257</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Adnan Shereen, M" uniqKey="Adnan Shereen M">M. Adnan Shereen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alharbi, N K" uniqKey="Alharbi N">N.K. Alharbi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Assiri, A" uniqKey="Assiri A">A. Assiri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bassetti, M" uniqKey="Bassetti M">M. Bassetti</name></author><author><name sortKey="Vena, A" uniqKey="Vena A">A. Vena</name></author><author><name sortKey="Giacobbe, D R" uniqKey="Giacobbe D">D.R. Giacobbe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Caly, L" uniqKey="Caly L">L. Caly</name></author><author><name sortKey="The Fda Approved Drug Ivermectin Inhibits The Replication Of Sars Cov In Vitro" uniqKey="The Fda Approved Drug Ivermectin Inhibits The Replication Of Sars Cov In Vitro">The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cao, B" uniqKey="Cao B">B. Cao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carlos, W G" uniqKey="Carlos W">W.G. Carlos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cascella, M" uniqKey="Cascella M">M. Cascella</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, J F W" uniqKey="Chan J">J.F.-W. Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, K S" uniqKey="Chan K">K.S. Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, H" uniqKey="Chen H">H. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, L" uniqKey="Chen L">L. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, N" uniqKey="Chen N">N. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, N" uniqKey="Chen N">N. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, W" uniqKey="Chen W">W. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheng, Y" uniqKey="Cheng Y">Y. Cheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Christian, M D" uniqKey="Christian M">M.D. Christian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chu, C M" uniqKey="Chu C">C.M. Chu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Covid In Children" uniqKey="Covid In Children">COVID-19 in Children</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Crouch, E C" uniqKey="Crouch E">E.C. Crouch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cui, J" uniqKey="Cui J">J. Cui</name></author><author><name sortKey="Li, F" uniqKey="Li F">F. Li</name></author><author><name sortKey="Shi, Z L" uniqKey="Shi Z">Z.L. Shi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dong, L" uniqKey="Dong L">L. Dong</name></author><author><name sortKey="Hu, S" uniqKey="Hu S">S. Hu</name></author><author><name sortKey="Gao, J" uniqKey="Gao J">J. Gao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dong, L" uniqKey="Dong L">L. Dong</name></author><author><name sortKey="Hu, S" uniqKey="Hu S">S. Hu</name></author><author><name sortKey="Gao, J" uniqKey="Gao J">J. Gao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Doremalen, N" uniqKey="Van Doremalen N">N. van Doremalen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duan, K" uniqKey="Duan K">K. Duan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Elfiky, A A" uniqKey="Elfiky A">A.A. Elfiky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Falsey, A R" uniqKey="Falsey A">A.R. Falsey</name></author><author><name sortKey="Walsh, E E" uniqKey="Walsh E">E.E. Walsh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fan, C" uniqKey="Fan C">C. Fan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gao, J" uniqKey="Gao J">J. Gao</name></author><author><name sortKey="Tian, Z" uniqKey="Tian Z">Z. Tian</name></author><author><name sortKey="Yang, X" uniqKey="Yang X">X. Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gu, J" uniqKey="Gu J">J. Gu</name></author><author><name sortKey="Han, B" uniqKey="Han B">B. Han</name></author><author><name sortKey="Wang, J" uniqKey="Wang J">J. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guan, W J" uniqKey="Guan W">W.J. Guan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guan, Y" uniqKey="Guan Y">Y. Guan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Holshue, M L" uniqKey="Holshue M">M.L. Holshue</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huang, C" uniqKey="Huang C">C. Huang</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Jawhara, S" uniqKey="Jawhara S">S. Jawhara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ji, W" uniqKey="Ji W">W. Ji</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jin, Y H" uniqKey="Jin Y">Y.-H. Jin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kliegman, R M" uniqKey="Kliegman R">R.M. Kliegman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, P I" uniqKey="Lee P">P.-I. Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lei, J" uniqKey="Lei J">J. Lei</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, G" uniqKey="Li G">G. Li</name></author><author><name sortKey="De Clercq, E" uniqKey="De Clercq E">E. De Clercq</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, H" uniqKey="Li H">H. Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, Q" uniqKey="Li Q">Q. Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, Z" uniqKey="Li Z">Z. Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lim, J" uniqKey="Lim J">J. Lim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, L" uniqKey="Liu L">L. Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, H" uniqKey="Lu H">H. Lu</name></author><author><name sortKey="Stratton, C W" uniqKey="Stratton C">C.W. Stratton</name></author><author><name sortKey="Tang, Y W" uniqKey="Tang Y">Y.-W. Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ludvigsson, J F" uniqKey="Ludvigsson J">J.F. Ludvigsson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maclennan, S" uniqKey="Maclennan S">S. MacLennan</name></author><author><name sortKey="Barbara, J A" uniqKey="Barbara J">J.A. Barbara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mahase, E" uniqKey="Mahase E">E. Mahase</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maxwell, C" uniqKey="Maxwell C">C. Maxwell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nijuan, X" uniqKey="Nijuan X">X. Nijuan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Onder, G" uniqKey="Onder G">G. Onder</name></author><author><name sortKey="Rezza, G" uniqKey="Rezza G">G. Rezza</name></author><author><name sortKey="Brusaferro, S" uniqKey="Brusaferro S">S. Brusaferro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Organization W H" uniqKey="Organization W H">Organization, W.H</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Phan, L T" uniqKey="Phan L">L.T. Phan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rabenau, H F" uniqKey="Rabenau H">H.F. Rabenau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raj, V S" uniqKey="Raj V">V.S. Raj</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rayner, C R" uniqKey="Rayner C">C.R. Rayner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Riou, J" uniqKey="Riou J">J. Riou</name></author><author><name sortKey="Althaus, C L" uniqKey="Althaus C">C.L. Althaus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roldao, A" uniqKey="Roldao A">A. Roldao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saglietto, A" uniqKey="Saglietto A">A. Saglietto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schwartz, D A" uniqKey="Schwartz D">D.A. Schwartz</name></author><author><name sortKey="Graham, A L" uniqKey="Graham A">A.L. Graham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shimabukuro Vornhagen, A" uniqKey="Shimabukuro Vornhagen A">A. Shimabukuro-Vornhagen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sodhi, M" uniqKey="Sodhi M">M. Sodhi</name></author><author><name sortKey="Etminan, M" uniqKey="Etminan M">M. Etminan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sohrabi, C" uniqKey="Sohrabi C">C. Sohrabi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Su, S" uniqKey="Su S">S. Su</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Griensven, J" uniqKey="Van Griensven J">J. Van Griensven</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, J" uniqKey="Wang J">J. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, L S" uniqKey="Wang L">L.S. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, M" uniqKey="Wang M">M. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, P" uniqKey="Wang P">P. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, W" uniqKey="Wang W">W. Wang</name></author><author><name sortKey="Tang, J" uniqKey="Tang J">J. Tang</name></author><author><name sortKey="Wei, F" uniqKey="Wei F">F. Wei</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Webster, R G" uniqKey="Webster R">R.G. Webster</name></author><author><name sortKey="Govorkova, E A" uniqKey="Govorkova E">E.A. Govorkova</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weiss, S R" uniqKey="Weiss S">S.R. Weiss</name></author><author><name sortKey="Navas Martin, S" uniqKey="Navas Martin S">S. Navas-Martin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Whitworth, J" uniqKey="Whitworth J">J. Whitworth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, Z" uniqKey="Wu Z">Z. Wu</name></author><author><name sortKey="Mcgoogan, J M" uniqKey="Mcgoogan J">J.M. McGoogan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xiao, F" uniqKey="Xiao F">F. Xiao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xiao, Y" uniqKey="Xiao Y">Y. Xiao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, S" uniqKey="Yang S">S. Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, Y" uniqKey="Yang Y">Y. Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, C" uniqKey="Zhang C">C. Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, Q" uniqKey="Zhang Q">Q. Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, T" uniqKey="Zhang T">T. Zhang</name></author><author><name sortKey="Wu, Q" uniqKey="Wu Q">Q. Wu</name></author><author><name sortKey="Zhang, Z" uniqKey="Zhang Z">Z. Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y. Zhang</name></author><author><name sortKey="Xu, J M" uniqKey="Xu J">J.M. Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zheng, F" uniqKey="Zheng F">F. Zheng</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Zhou, P" uniqKey="Zhou P">P. Zhou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhou, Y" uniqKey="Zhou Y">Y. Zhou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zu, Z Y" uniqKey="Zu Z">Z.Y. Zu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Genet Evol</journal-id><journal-id journal-id-type="iso-abbrev">Infect. Genet. Evol</journal-id><journal-title-group><journal-title>Infection, Genetics and Evolution</journal-title></journal-title-group><issn pub-type="ppub">1567-1348</issn><issn pub-type="epub">1567-7257</issn><publisher><publisher-name>Elsevier Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">7166307</article-id><article-id pub-id-type="publisher-id">S1567-1348(20)30158-1</article-id><article-id pub-id-type="doi">10.1016/j.meegid.2020.104327</article-id><article-id pub-id-type="publisher-id">104327</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name><surname>El-Aziz</surname><given-names>Tarek Mohamed Abd</given-names></name><email>mohamedt1@uthscsa.edu</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">⁎</xref></contrib><contrib contrib-type="author" id="au0010"><name><surname>Stockand</surname><given-names>James D.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib></contrib-group><aff id="af0005"><label>a</label>Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA</aff><aff id="af0010"><label>b</label>Zoology Department, Faculty of Science, Minia University, El-Minia 61519, Egypt</aff><author-notes><corresp id="cr0005"><label>⁎</label>Corresponding author Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA. <email>mohamedt1@uthscsa.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>19</day><month>4</month><year>2020</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="epub"><day>19</day><month>4</month><year>2020</year></pub-date><elocation-id>104327</elocation-id><history><date date-type="received"><day>5</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>15</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>Published by Elsevier B.V.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder></copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab0005"><p>Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year.</p></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="li0005"><label>•</label><p id="p0005">A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province in China.</p></list-item><list-item id="li0010"><label>•</label><p id="p0010">On Feb 11, 2020, the WHO announced a new name for the epidemic disease as 2019-new coronavirus disease (2019-nCoV and now known as COVID-19).</p></list-item><list-item id="li0015"><label>•</label><p id="p0015">COVID-19 has become a major global health concern and the WHO declared the coronavirus outbreak as a global pandemic on March 2020.</p></list-item><list-item id="li0020"><label>•</label><p id="p0020">As of March 29, 2020, COVID-19 has affected more than 660,099 patients in 199 countries and left around 30,667 deaths worldwide.</p></list-item><list-item id="li0025"><label>•</label><p id="p0025">Unfortunately, no medicine or anti-virus vaccine has yet been officially approved to treat COVID-19-associated pathologies.</p></list-item></list></p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>Coronavirus</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>Severe acute respiratory syndrome</kwd><kwd>Pathogenesis</kwd><kwd>Therapy</kwd><kwd>Vaccines</kwd></kwd-group><kwd-group id="ks0010"><title>Abbreviations</title><kwd>SARS, Severe Acute Respiratory Syndrome</kwd><kwd>MERS, Middle East Respiratory Syndrome</kwd><kwd>SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus-2</kwd><kwd>COVID-19, Coronavirus Disease 2019</kwd><kwd>WHO, World Health Organization</kwd><kwd>FDA, Food and Drug Administration</kwd><kwd>AlphaCoV, Alpha-coronavirus</kwd><kwd>BetaCoV, Beta-coronavirus</kwd><kwd>DeltaCoV, Delta-coronavirus</kwd><kwd>GammaCoV, Gamma-coronavirus</kwd><kwd>CDC, Centers for Disease Control and Prevention</kwd><kwd>RT-PCR, Real-Time Reverse Transcription Polymerase Chain Reaction</kwd><kwd>CT, Computed tomography</kwd><kwd>VLP, Virus-Like Particle</kwd><kwd>IL-6, Interleukin-6</kwd></kwd-group></article-meta></front></pmc><affiliations><list><country><li>Égypte</li><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="El Aziz, Tarek Mohamed Abd" sort="El Aziz, Tarek Mohamed Abd" uniqKey="El Aziz T" first="Tarek Mohamed Abd" last="El-Aziz">Tarek Mohamed Abd El-Aziz</name></region><name sortKey="Stockand, James D" sort="Stockand, James D" uniqKey="Stockand J" first="James D." last="Stockand">James D. Stockand</name></country><country name="Égypte"><noRegion><name sortKey="El Aziz, Tarek Mohamed Abd" sort="El Aziz, Tarek Mohamed Abd" uniqKey="El Aziz T" first="Tarek Mohamed Abd" last="El-Aziz">Tarek Mohamed Abd El-Aziz</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003F85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:7166307
|texte= Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:NONE" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |